Alnylam Pharmaceuticals, Inc. vs. Silence Therapeutics GMBH
Explore the PTAB proceeding PGR2018-00067 filed by Alnylam Pharmaceuticals, Inc. on 2018-06-11. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
PGR2018-00067
Filing Date
2018-06-11
Accorded Filing Date
2018-06-11
Institution Decision Date
—
Last Modified Date
2022-10-07
Proceeding Type
PGR
Termination Date
2018-12-18
Trial Status
Terminated-Settled
Parties & Counsel
Petitioner
Alnylam Pharmaceuticals, Inc.
Represented By
Scott ReedPatent Owner / Respondent
Silence Therapeutics GMBH
Represented By
Matthew I. KreegerPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Terminated-Settled
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 38651 | Michael Ward | +1 415-268-6237 |
| 39933 | Robert Cerpa | +1 650-813-5715 |
| 40130 | Catherine Polizzi | +1 650-813-5651 |
| 45640 | Jonathan Bockman | +1 202-791-8570 |
| 46813 | Parisa Jorjani | +1 415-268-7000 |
| 48231 | Mehran Arjomand | +1 213-892-5630 |
| 50713 | Patricia Tsao | +1 415-268-6642 |
| 51934 | Christine Lekutis | +1 415-268-7060 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 9,758,784 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 2,017,601 | European Counterpart (EP) | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 1,389,637 B1 | European Counterpart (EP) | View Official Patent → |
| 🇺🇸 United States | US 40,254,102 P | US Continuation / Sibling | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 3,008,383 | European Counterpart (EP) | View Official Patent → |
| 🇺🇸 United States | US 7,452,987 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,893,245 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,324,370 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,933,215 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,222,092 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,695,423 B2 | US Continuation / Sibling | View Official Patent → |
Alnylam Pharmaceuticals, Inc. v. Silence Therapeutics GMBH